This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
H5N1 VLP Vaccine
Mitsubishi Tanabe Pharma Corporation
Drug Names(s): H5 VLP Pandemic Influenza Vaccine
Description: Medicago's H5N1 vaccine was formulated to protect against the avian influenza virus. It is manufactured in Nicotiana benthamiana, a relative of the tobacco plant, using the Company's proprietary VLP technology.
VLPs have several advantages over traditional influenza vaccines. They resemble the virus, allowing them to be recognized readily by the body's immune system, however, they lack the core genetic material making them non-infectious and unable to replicate. Medicago's VLP-based vaccine has shown in preclinical studies it can provide cross- protection against different strains of avian flu, such as the Vietnam and Turkey strains.
Medicago and Philip Morris
In September 2012, Medicago announced the signing of a licensing agreement with Philip Morris Products SA (PMP), a subsidiary of Philip Morris International Inc. Under the agreement, Medicago grants PMP an exclusive license to develop, commercialize and manufacture Medicago's pandemic and seasonal influenza vaccines for China. Medicago will receive an upfront payment of US$4.5 million from PMP. In addition, Medicago is eligible to receive development milestone payments totalling US$7.5 million, as well as royalty payments on any future sales of pandemic and seasonal influenza vaccines by PMP in China which utilize the Medicago technologies.
Immune Design and Medicago
In June 2013, Immune Design and Medicago entered a license agreement providing Medicago the use and commercialization of Immune Design's proprietary synthetic Toll-like Receptor 4 agonist, Glucopyranosyl Lipid A (GLA). Medicago has the option to use Immune Design's...See full deal structure in Biomedtracker
Partners: Philip Morris International Inc.
H5N1 VLP Vaccine News
Additional information available to subscribers only: